<code id='478F7574EE'></code><style id='478F7574EE'></style>
    • <acronym id='478F7574EE'></acronym>
      <center id='478F7574EE'><center id='478F7574EE'><tfoot id='478F7574EE'></tfoot></center><abbr id='478F7574EE'><dir id='478F7574EE'><tfoot id='478F7574EE'></tfoot><noframes id='478F7574EE'>

    • <optgroup id='478F7574EE'><strike id='478F7574EE'><sup id='478F7574EE'></sup></strike><code id='478F7574EE'></code></optgroup>
        1. <b id='478F7574EE'><label id='478F7574EE'><select id='478F7574EE'><dt id='478F7574EE'><span id='478F7574EE'></span></dt></select></label></b><u id='478F7574EE'></u>
          <i id='478F7574EE'><strike id='478F7574EE'><tt id='478F7574EE'><pre id='478F7574EE'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:22139
          Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT
          Molly Ferguson for STAT

          The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

          Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

          advertisement

          The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Medicare Advantage proposed rates disappoint insurers
          Medicare Advantage proposed rates disappoint insurers

          AdobeYou’rereadingthewebversionofHealthCareInc., STAT’sweeklynewsletter followingtheflowofmoneyinmed

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          New CMS data security rules will hurt Medicare, Medicaid research

          AdobeGroundbreakingresearchmorethanadecadeagoshowedthatalmostone-fifthofpeopleenrolledinMedicarewere